• About Us
  • Activity
  • Advertising
  • Books
  • Business
  • Contact
  • Dashboard
  • EB5
  • Entertainment
  • feedback
  • Forgot Your Password?
  • Government
  • Home
  • Home 20723
  • Interviews
  • Login
  • Members
  • Meme generator
  • National
  • Nevada
  • Nevada News and Views
  • Newsmax
  • NN&V Ads
  • Opinion
  • Pick a New Password
  • Politics
  • Polls
  • Privacy Policy
  • Profile
  • Recent comments by me
  • Recent comments on my posts
  • Register
  • Submit post
  • Subscribe
  • Subscription Confirmation
  • Survey
  • Survey
  • Terms of Service
  • Today’s Top 10
  • Travel
  • Travel
  • Travel
  • Welcome!
  • Yop Poll Archive
Nevada News and Views
  • About Us
  • Contact
  • More
    • Opinion
  • Facebook

  • Twitter

  • Pinterest

  • RSS

Opinion

Laxalt and 42 States Reach $19.5 Million Settlement With Pharmaceutical Company for Deceptive Trade Practices Related to Drug Abilify

Laxalt and 42 States Reach $19.5 Million Settlement With Pharmaceutical Company for Deceptive Trade Practices Related to Drug Abilify
Chuck Muth
December 8, 2016

(Office of the Attorney General) – Today, Nevada Attorney General Adam Paul Laxalt, along with attorneys general representing 42 other states and the District of Columbia, announced a $19.5 million dollar settlement with Bristol-Myers Squibb Company (BMS) related to the drug company’s alleged improper marketing of Abilify. Abilify is the brand name for the prescription drug aripiprazole, and is an atypical antipsychotic drug. The settlement resolved allegations that BMS engaged in unfair or deceptive trade practices while marketing the drug.

Abilify was originally approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2002. Since then, the FDA has approved various formulations of Abilify for several uses. In their complaint, the States allege that BMS improperly promoted Abilify for use in elderly patients who exhibited symptoms consistent with dementia and Alzheimer’s disease, without FDA approval for these uses and without first establishing the drug’s safety and efficacy for these uses. Despite receiving a “black box” warning stating that elderly patients with dementia-related psychosis who are treated with antipsychotic drugs have an increased risk of death, the promotion of Abilify to elderly patients was not halted.

Adam Laxalt, Nevada Attorney General

“Pharmaceutical companies have a responsibility to accurately promote their medications, and should not mislead consumers in a way that could jeopardize their health and wellbeing,” said Laxalt.

Other allegations contained in the complaint include that BMS promoted Abilify for uses in children not approved by the FDA, that BMS minimized and misrepresented risks associated with the drug, and that BMS overstated the findings of scientific studies regarding Abilify.

The active ingredient in Abilify, aripiprazole, is now available as a generic, but several product formulations are still protected by patent. Under the terms of the settlement, BMS’ marketing of any formulation containing the active ingredient aripiprazole will be restricted. BMS will be prohibited from making false or misleading claims about Abilify, about its safety or efficacy in comparison with other drugs, and about the implications of clinical studies relating to the drug. The company will also be subject to limitations on financial incentives to sales representatives and health care providers, dissemination of information that may promote off-label use of Abilify, and other practices affecting off-label promotion.

In addition to Nevada, other states who participated in this settlement include: Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia, and Wisconsin. The District of Columbia also participated in this settlement.

Chief Deputy Attorney General JoAnn Gibbs and Deputy Attorney General Laura Tucker represented Nevada in this matter.

As a result of this settlement, Nevada will receive $289,456.

 

The Office of the Attorney General is headed by Attorney General Adam Paul Laxalt. The office’s primary role is to serve the citizens of Nevada and to work to make the state a stronger, safer and freer place to live. Visit its website at AG.NV.gov.

Prev postNext post

Related Items
Opinion
December 8, 2016
Chuck Muth

Related Items

More in Opinion

Amodei Statement on Debt Ceiling Bill

Chuck MuthJune 1, 2023
Read More

Tark: Trans “Rights” … and Wrongs

Chuck MuthMay 26, 2023
Read More

Stone: The Truth About AB 250: Will Patients Really Benefit?

NN&V StaffMay 26, 2023
Read More

“Ungrateful Miscreants”: Miller, Segerblom Insult Local Small Business Owners

NN&V StaffMay 24, 2023
Read More

Quarter-Million Dollar Ad Campaign Targets Nevada Legislators for Trapping Hispanic Families in Unsafe Schools

NN&V StaffMay 22, 2023
Read More

Nevada News & Views: May 20, 2023

NN&V StaffMay 20, 2023
Read More
Scroll for more
Tap

Subscribe Free By Email

Looking for the best in breaking news and conservative views? Let Chuck do all the work for you! Subscribe to his FREE "Muth's Truths" e-newsletter.

* indicates required
Nevada News and Views
Nevada News & Views is an educational project of Citizen Outreach Foundation, a non-partisan IRS-approved 501(c)(3) organization. It is not associated or affiliated with any political party or group. Nevada News & Views is accessible by the public at no cost. It funds its operations through tax-deductible contributions from donors and supporters and does not accept government money or grants.

TAGS

Featured Article Muths truth

Copyright © 2023 Citizen Outreach | Maintained by VirtualAlly

Mitchell: Telling like it is about Harry Reid
Yes, Kap, Black Lives Do Matter… So Show It!